Mr. Gabriel Fahel reports

CYBIN ANNOUNCES RESULTS OF ANNUAL MEETING OF SHAREHOLDERS

Cybin Inc. has released the voting results for each of the matters presented at the company's annual meeting of shareholders held on Aug. 18, 2025. There were 90 shareholders represented in person or by proxy at the meeting holding 11,264,212 common shares, representing 48.92 per cent of Cybin's total issued and outstanding common shares as at the record date for the meeting. The voting results for each matter presented at the meeting are set out below.

1. Appointment of auditor

Zeifmans LLP was appointed auditor of Cybin until the next annual meeting of shareholders at renumeration to be fixed by the directors of Cybin. Voting results are set out below.

     Votes for             Votes withheld  

Number             %      Number         %      

11,206,201    99.485      58,010    0.515% 

2. Number of directors

The special resolution to set the number of directors of Cybin at six was approved by at least two-thirds of the votes casts by the shareholders who voted in respect of the resolution present or represented by proxy at the meeting. Voting results are set out below.

      Votes for             Votes against  

Number              %      Number        %    

10,470,055     92.950     794,156    7.050

3. Election of directors

Each of the nominees for election as director listed in Cybin's management information circular dated July 14, 2025, was elected as directors of Cybin for the ensuing year or until successors are elected or appointed. Voting results are set out below.

                          Votes for          Votes withheld   
                       
                       Number        %      Number        %   

Theresa Firestone   4,786,111   86.161     768,746   13.839
Grant Froese        4,787,135   86.179     767,722   13.821
Paul Glavine        4,789,854   86.228     765,004   13.772
Eric Hoskins        3,406,590   61.326   2,148,267   38.674
Mark Lawson         4,788,272   86.200     766,585   13.800
Eric So             4,779,295   86.038     775,563   13.962 

George Tziras did not stand for re-election as a director. The company thanks Mr. Tziras for his past service.

About Cybin Inc.

Cybin is a late-stage breakthrough neuropsychiatry company committed to revolutionizing mental health care by developing new and innovative next-generation treatment options to address the large unmet need for people who suffer from mental health conditions.

With promising proof-of-concept data, Cybin is working to change the mental health treatment landscape through the introduction of intermittent treatments that provide long-lasting results. The company is currently developing CYB003, a proprietary deuterated psilocin analogue, in phase 3 studies for the adjunctive treatment of major depressive disorder, and CYB004, a proprietary deuterated N, N-dimethyltryptamine molecule in a phase 2 study for generalized anxiety disorder. The company also has a research pipeline of investigational 5-HT-receptor-focused compounds.

Founded in 2019, Cybin is operational in Canada, the United States, the United Kingdom, the Netherlands and Ireland.

We seek Safe Harbor.